Pre-order Enquiry
Request Free Sample
Global Antibody Drug Conjugates Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Global Market Forecasts to 2023
SKU ID : RNCOS-11697369 | Publishing Date : 18-Apr-2018 | No. of pages : 110
Request Sample
Request Customization
Check DiscountsDetailed TOC of Global Antibody Drug Conjugates Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Global Market Forecasts to 2023
1. Analyst View2. Research Methodology
3. Antibody Drug Conjugate (ADC) - An Introduction
4. Global Antibody Drug Conjugates Market Outlook to 2023
5. Commercialized Antibody Drug Conjugates
5.1 ADCETRIS
5.2 Kadcyla
5.3 Mylotarg
5.4 Besponsa
6. Antibody Drug Conjugates Pipeline Analysis
6.1 By Companies
6.1.1 By Clinical Phase
6.1.2 By Indication
6.1.3 By Drug
6.1.4 By Type of Linker
6.1.5 By Technology
6.2 By Research Organizations
6.2.1 By Phase
6.2.2 By Indication
6.2.3 By Drug
6.2.4 By Type of Linker
6.2.5 By Technology
7. Drivers and Challenges
7.1 Drivers
7.1.1 Rising Global Cancer Epidemics
7.1.2 Advances in Linking Technologies Re-Instills Hope in ADC
7.1.3 Efforts towards Patent Protection to Drive ADC Market
7.1.4 Increasing Demand for Antibody Drug Conjugates
7.2 Challenges
7.2.1 Production Hurdles and Cost
7.2.2 Inadequacy of Experienced Manufacturers
7.2.3 Regulatory Challenges
8. Major Potential Antibody Drug Conjugates in Pipeline
8.1 By Companies
8.1.1 Glembatumumab Vedotin Therapeutics/CDX-011 - Celldex
8.1.2 Coltuximab Ravtansine/SAR3419 - ImmunoGen Inc.
8.1.3 Indatuximab Ravtansine/BT-062 – Biotest AG
8.1.4 Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals
8.1.5 Polatuzumab Vedotin/RG7596 - F. Hoffman-La Roche Ltd.
8.1.6 DMUC-4064A/RG7882 - F. Hoffman-La Roche Ltd.
8.1.7 Mirvetuximab Soravtansine/IMGN853 - ImmunoGen Inc.
8.2 By Research Organizations
8.2.1 SGM-101 - SurgiMab in Collaboration with Center for Human Drug Research, Netherlands
8.2.2 MOC31-PE - Creative Biolabs in Collaboration with Oslo University Hospital
9. Trends and Developments
9.1 ADC at the Forefront of Treating Hematological Malignancies
9.2 ADCs Proving Advantageous for Breast Cancer Patients
10. Strategic Alliances in the Global Antibody Drug Conjugates Industry
11. Competitive Assessment
11.1 Seattle Genetics, Inc.
11.2 F. Hoffman-La Roche Ltd.
11.3 Pfizer Inc.
11.4 ImmunoGen, Inc.
11.5 Bayer AG
11.6 Takeda Pharmaceutical Company Limited
11.7 Immunomedics, Inc.
11.8 Oxford BioTherapeutics
11.9 Concortis Biotherapeutics
11.10 NBE-Therapeutics
List of Figures, Tables and Charts Available in Global Antibody Drug Conjugates Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Global Market Forecasts to 2023
List of Tables:Table 5-1: Global - Incidence of Hodgkin Lymphoma, 2012, 2015, 2020, & 2025
Table 5-2: Global - Incidence of Non-Hodgkin Lymphoma, 2012, 2015, 2020, & 2025
Table 5-3: Major Ongoing Trials for ADCETRIS
Table 5-4: Global - Incidence of Breast Cancer, 2012, 2015, 2020, & 2025
Table 5-5: Major Ongoing Trials for Kadcyla
Table 5-6: Major Ongoing Trials for Mylotarg
Table 5-7: Major Ongoing Trials for Besponsa
Table 6-1: Global - ADC Pipeline of Companies
Table 6-2: Global - ADC Pipeline of Research Organization
Table 10-1: Major Strategic Alliances in the Global Antibody Drug Conjugates Industry (2014-2017)
Table 11-1: Seattle Genetics, Inc. - Key Financials (Million US$), 2014-2016
Table 11-2: Seattle Genetics, Inc. - ADC Product Portfolio
Table 11-3: Seattle Genetics, Inc. - ADCs in Pipeline
Table 11-4: F. Hoffman-La Roche Ltd. - Key Financials (Million US$), 2014-2016
Table 11-5: F. Hoffman-La Roche Ltd. - ADC Product Portfolio
Table 11-6: F. Hoffman-La Roche Ltd. - ADCs in Pipeline
Table 11-7: Pfizer Inc. - Key Financials (Million US$), 2014-2016
Table 11-8: Pfizer Inc. - ADC Product Portfolio
Table 11-9: Pfizer Inc. - ADCs in Pipeline
Table 11-10: ImmunoGen, Inc. - Key Financials (Million US$), 2014-2016
Table 11-11: ImmunoGen, Inc. - ADCs in Pipeline
Table 11-12: Bayer AG - Key Financials (Million US$), 2014-2016
Table 11-13: Bayer AG - ADCs in Pipeline
Table 11-14: Takeda Pharmaceutical Company Limited - Key Financials (Million US$), 2014-2016
Table 11-15: Takeda Pharmaceutical Company Limited - ADCs in Pipeline
Table 11-16: Immunomedics, Inc. - Key Financials (Million US$), 2015-2017
Table 11-17: Immunomedics, Inc. - ADCs in Pipeline
Table 11-18: Oxford BioTherapeutics - ADCs in Pipeline
Table 11-19: Concortis Biotherapeutics - ADCs in Pipeline
Table 11-20: NBE-Therapeutics - ADCs in Pipeline
List of Figures:
Figure 3-1: ADC - Mechanism of Action
Figure 4-1: Global - ADC Market (Billion US$), 2016, 2017 & 2023
Figure 5-1: Global - ADCETRIS Sales (Million US$), 2016 & 2017
Figure 5-2: Global - Kadcyla Sales (Million US$), 2016 & 2017
Figure 6-1: Global - ADCs Pipeline by Developing Organizations (%), 2017
Figure 6-2: Global - ADC Pipeline of Companies by Clinical Phase (%), 2017
Figure 6-3: Global - ADC Pipeline of Companies by Indication (%), 2017
Figure 6-4: Global - ADC Pipeline of Companies by Drug (%), 2017
Figure 6-5: Global - ADC Pipeline of Companies by Type of Linker (%), 2017
Figure 6-6: Global - ADC Pipeline of Companies by Technology (%), 2017
Figure 6-7: Global - ADC Pipeline of Research Organization by Clinical Phase (%), 2017
Figure 6-8: Global - ADC Pipeline of Research Organization by Indication (%), 2017
Figure 6-9: Global - ADC Pipeline of Research Organization by Drug (%), 2017
Figure 6-10: Global - ADC Pipeline of Research Organization by Type of Linker (%), 2017
Figure 6-11: Global - ADC Pipeline of Research Organization by Technology (%), 2017
Figure 11-1: F. Hoffman-La Roche Ltd. - Group Sales Breakup by Business Segments (%), 2016
Figure 11-2: Pfizer Inc. - Revenue Breakup by Business Segments (%), 2016
Figure 11-3: Pfizer Inc. - Revenue Breakup by Geography (%), 2016
Figure 11-4: Bayer AG - Sales Breakup by Business Segments (%), 2016
Figure 11-5: Bayer AG - Net Sales Breakup by Geography (%), 2016
Figure 11-6: Takeda Pharmaceutical Company Limited - Ethical Drugs Revenue Breakup by Geography (%), 2016
Figure 11-7: Immunomedics, Inc. - Revenue Breakup by Geography (%), 2017
